FDA forwards Avandia 'conflict' probe to HHS

Share this article:
As it wrestles with the drug's safety issues, including public disagreements about them within its own ranks, FDA referred in July to the HHS Office of Inspector General the case of an Avandia advisory committee panel member who had an alleged conflict of interest related to previous work performed on behalf of GlaxoSmithKline that was not disclosed.

Endocrinologist David Capuzzi was one of only three committee members to vote to recommend that Avandia remain on the market with no new labeling or restrictions on its use. He reportedly received payments from GSK for speaking engagements he performed for them.

“FDA has completed its fact-gathering process and has referred the Dr. Capuzzi matter to the HHS Office of Inspector General,” FDA spokeswoman Karen Riley said. “FDA is prohibited by law to release Dr. Capuzzi's or any member's confidential financial disclosure form.”

Capuzzi has said he wasn't specifically asked about his work with GSK that involved an unrelated drug. Capuzzi also said that in his own practice he doesn't prescribe Avandia or any newer diabetes drug, preferring to use older metformin drugs.
Share this article:
You must be a registered member of MMM to post a comment.

Next Article in Features

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Features

Read the complete September 2014 Digital Edition

Read the complete September 2014 Digital Edition

Click the above link to access the complete Digital Edition of the August 2014 issue of MM&M, with all text, charts and pictures.

Medical marketing needs mainstream Mad Men

Medical marketing needs mainstream Mad Men

Agencies must generate emotional resonance with the target audience, not unlike Apple, Pepsi or Nike

Are discounts cutting out co-pays?

GSK's decision to cut Advair's price spurred some PBMs to put it back on formulary. Will drugmaker discounts diminish the need for loyalty programs? How can these programs stay relevant beyond giving co-pay assistance?